N/A
Completed N=29
Collaborative Research Group for Necrotizing Enterocolitis
Source: ClinicalTrials.gov NCT00828451 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Mar 2018
Primary outcomePrimary: Salivary EGF (Epidermal Growth Factor) Protein Levels — 15 picograms EGF/ microgram of protein
Summary
This proposal will test the hypothesis that synthesis and catabolism of epidermal growth factor (EGF), the genotype of the EGF gene, and the microbiome interact to influence EGF expression in infants at risk for necrotizing enterocolitis (NEC).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Salivary EGF (Epidermal Growth Factor) Protein Levels |
15 | — |
| PRIMARY Urinary EGF Protein Levels |
48 | — |
| SECONDARY EGF Gene Sequencing |
11 | — |
Eligibility Criteria
Inclusion Criteria
- gestation 32 weeks or less
- 1 week of age or less
- intravenous line in place for clinical purposes
Exclusion Criteria
- imminent death
- active infection
- pre-existing diagnosis of NEC
- fluid or electrolyte imbalance
Data sourced from ClinicalTrials.gov (NCT00828451). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.